Jeanne Tie, MD, MBChB, on Colon Cancer: New Data on ctDNA Guiding Adjuvant Therapy
2024 ASCO Annual Meeting
Jeanne Tie, MD, MBChB, of Peter MacCallum Cancer Centre, discusses data on survival and updated 5-year results from the DYNAMIC trial, which supports a role for circulating tumor DNA (ctDNA) analysis, including serial sampling, in the management of patients with stage II colon cancer (Abstract 108).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So the dynamic is a randomized trial looking at the utility of using CtDNA to guide adjuvant treatment in stage two colon cancer. The rationale behind the study is the fact that the role of adjuvant chemotherapy remains debatable in stage two colon cancer where surgery cured the majority of patients and to date, there has been very little evidence of survival benefit with the use of adjuvant chemotherapy. Our prior work have shown that detection of CtDNA after surgery is highly prognostic, where almost all patient recurred if left untreated. So this is a non-inferiority study that randomized patient to two-thirds receiving CtDNA guided management and one-third of standard management.
So in the CtDNA guided group, patient with a positive result after surgery receive adjuvant chemotherapy and patient with a negative result were just observed. So the key findings from the study is that we have reduced the use of adjuvant chemotherapy by using CtDNA compared to standard management from 28% down to 15%, but we did not compromise recurrence-free survival. The updated results from dynamics showed that even at 5 years, the recurrence-free survival was 88.3% in the CtDNA guided group, and 87.2% with that of management of not using the blood test and the lower bound of the 95 confidence interval remains above the non-inferiority margin, again, confirming the non-inferiority of this approach.
The overall survival between the two arms are similarly very favorable, ranging around 93%, which is very impressive. Intriguingly, we found that more than half the patient, substantial proportion of the death events in the study were not due to colorectal cancer recurrence resulting in a disease-specific survival, exceeding 97% across both arms. Another interesting finding is that we collected serial bloods on patient who have CtDNA positive and receive adjuvant chemotherapy. We found a very high clearance rate of 87.5% of CtDNA clearance following adjuvant chemotherapy, and patients who cleared a CtDNA had exceedingly good recurrence-free survival compared to patient who did not clear their CtDNA.
So we also found that in untreated CtDNA negative T4 tumor, their overall survival is excellent at 19.6%. The implication for clinical practice is that using CtDNA to guide therapy compared to not having the blood test in stage two colon cancer can reduce the use of adjuvant chemotherapy without compromising patient's outcome and that CtDNA clearance rate is very high, supporting the benefit of adjuvant chemotherapy in this very high-risk population.
Related Videos
The ASCO Post Staff
David J. Andorsky, MD, of the Sarah Cannon Research Institute and Rocky Mountain Cancer Centers, discusses EPCORE NHL-6, an ongoing study of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). As outpatients, the study participants were given subcutaneous epcoritamab-bysp to see whether they could be safely monitored and cytokine-release syndrome appropriately managed in the outpatient setting (Abstract 7029).
The ASCO Post Staff
Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Dejan Juric, MD, of the Massachusetts General Hospital Cancer Center, discuss phase III findings on first-line use of inavolisib or placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer who relapsed within 12 months of completing adjuvant endocrine therapy (Abstract 1003).
The ASCO Post Staff
Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses 2.5-year follow-up data on epcoritamab monotherapy for patients with relapsed or refractory large B-cell lymphoma. The subcutaneous regimen continues to demonstrate durable responses (Abstract 7039).
The ASCO Post Staff
Omid Hamid, MD, of The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, discusses updated data on IMC-F106C, a novel bispecific protein that, in a phase I safety and efficacy study, exhibited clinical activity in patients with unresectable or metastatic cutaneous melanoma who were pretreated with immune checkpoint inhibitors. A phase III trial of IMC-F106C with nivolumab in the first-line setting of metastatic disease has been initiated (NCT06112314; Abstract 9507).
The ASCO Post Staff
Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center, discusses expanded data on the durability of complete response to dostarlimab-gxly, a PD-1 single-agent therapy administered to patients with locally advanced mismatch repair–deficient rectal cancer. The drug yielded recurrence-free responses, lasting longer than a year, without the need for chemotherapy, radiation, or surgery (LBA3512).